Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling-Reference-Cited by-同舟云学术

Progression of BRAF-induced thyroid cancer is associated with epithelial–mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling

Published:2011-03-07 Issue:28 Volume:30 Page:3153-3162
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Knauf J A,Sartor M A,Medvedovic M,Lundsmith E,Ryder M,Salzano M,Nikiforov Y E,Giordano T J,Ghossein R A,Fagin J A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc201144.pdf

Reference53 articles.

1. Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M et al. (2007). Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 92: 4712–4718.

2. Benjamini Y, Hochberg Y . (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57: 289–300.

3. Bravo SB, Pampin S, Cameselle-Teijeiro J, Carneiro C, Dominguez F, Barreiro F et al. (2003). TGF-beta-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-kappaB activation. Oncogene 22: 7819–7830.

4. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG et al. (2005). Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33: e175.

5. Depoortere F, Pirson I, Bartek J, Dumont JE, Roger PP . (2000). Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1). Mol Biol Cell 11: 1061–1076.

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Poorly differentiated thyroid carcinoma: molecular, clinico-pathological hallmarks and therapeutic perspectives;Panminerva Medica;2024-06

2. TERT accelerates BRAF mutant–induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis;Science Advances;2023-09

3. Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma;Endocrinology and Metabolism;2023-08-31

4. β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in BrafV600E-driven thyroid cancer cells;Frontiers in Immunology;2023-07-06

5. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy;Drug Resistance Updates;2023-05